Tianjin Lisheng Pharmaceutical Co Ltd (002393) — Net Asset Quality Index
Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Net Asset Quality Index of 83.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.53 Billion minus total liabilities of CN¥893.57 Million yields net assets of CN¥4.64 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 002393 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Tianjin Lisheng Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2006–2025)
This chart shows how Tianjin Lisheng Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 20 annual periods from 2006 to 2025. As of March 2026, the index stands at 83.9%, representing net assets of CN¥4.64 Billion against total assets of CN¥5.53 Billion CNY. See 002393 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Tianjin Lisheng Pharmaceutical Co Ltd (2006–2025)
The table below presents the year-by-year Net Asset Quality Index for Tianjin Lisheng Pharmaceutical Co Ltd from 2006 to 2025, covering 20 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 002393 market cap overview.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 84.0% | CN¥4.69 Billion | CN¥5.58 Billion | CN¥890.89 Million | ▲ +1.1 pp |
| 2024 | 83.0% | CN¥4.80 Billion | CN¥5.79 Billion | CN¥985.54 Million | ▼ -1.9 pp |
| 2023 | 84.8% | CN¥4.90 Billion | CN¥5.78 Billion | CN¥877.17 Million | ▲ +2.6 pp |
| 2022 | 82.2% | CN¥4.35 Billion | CN¥5.29 Billion | CN¥941.66 Million | ▼ -2.8 pp |
| 2021 | 85.0% | CN¥4.41 Billion | CN¥5.19 Billion | CN¥780.42 Million | ▼ -0.7 pp |
| 2020 | 85.7% | CN¥4.30 Billion | CN¥5.02 Billion | CN¥720.09 Million | ▲ +1.9 pp |
| 2019 | 83.8% | CN¥4.42 Billion | CN¥5.27 Billion | CN¥855.85 Million | ▲ +1.8 pp |
| 2018 | 82.0% | CN¥3.21 Billion | CN¥3.92 Billion | CN¥704.85 Million | ▼ -1.6 pp |
| 2017 | 83.6% | CN¥3.08 Billion | CN¥3.68 Billion | CN¥602.32 Million | ▼ -2.9 pp |
| 2016 | 86.5% | CN¥3.02 Billion | CN¥3.49 Billion | CN¥470.60 Million | ▼ -0.6 pp |
| 2015 | 87.1% | CN¥2.97 Billion | CN¥3.41 Billion | CN¥439.50 Million | ▼ -2.5 pp |
| 2014 | 89.6% | CN¥2.91 Billion | CN¥3.25 Billion | CN¥337.89 Million | ▼ -1.1 pp |
| 2013 | 90.7% | CN¥2.92 Billion | CN¥3.22 Billion | CN¥298.20 Million | ▼ -4.2 pp |
| 2012 | 95.0% | CN¥2.79 Billion | CN¥2.93 Billion | CN¥148.13 Million | ▼ -2.8 pp |
| 2011 | 97.8% | CN¥2.80 Billion | CN¥2.86 Billion | CN¥64.07 Million | ▲ +0.6 pp |
| 2010 | 97.2% | CN¥2.65 Billion | CN¥2.73 Billion | CN¥77.12 Million | ▲ +43.8 pp |
| 2009 | 53.4% | CN¥470.87 Million | CN¥882.13 Million | CN¥411.26 Million | ▼ -10.3 pp |
| 2008 | 63.7% | CN¥474.77 Million | CN¥745.35 Million | CN¥270.58 Million | ▲ +14.2 pp |
| 2007 | 49.4% | CN¥432.23 Million | CN¥874.11 Million | CN¥441.87 Million | ▼ -2.5 pp |
| 2006 | 51.9% | CN¥448.45 Million | CN¥863.49 Million | CN¥415.03 Million | — |